An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indivior Inc.; XenoPort, Inc.
• Treatments: Arbaclofen placarbil; Baclofen

Criteria

Inclusion Criteria:

• History and documentation of GERD diagnosed by a gastroenterologist, with symptoms (heartburn and/or regurgitation) on ≥ 3 days during the week prior to screening and prior to randomization

Exclusion Criteria:

• Current or historical endoscopic evidence of erosive esophagitis LA Classification Grade B, C, or D